HSP90AB1 and Huntington disease: Such observations enabled the design of Hsp90 α/β isoform‐selective inhibitors, and significantly reduced the amyloidogenic mutant huntingtin (mHTT) aggregates responsible for HD pathogenicity, while mitigating toxicity associated with pan‐inhibition [128, 129].